Determinants of sustained viral suppression in HIV-infected patients with self-reported poor adherence to antiretroviral therapy

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Glass, Tracy R ^a   Rotger, Margalida ^b   Telenti, Amalio ^b   Decosterd, Laurent ^b   Csajka, Chantal ^b,i   Bucher, Heiner C ^a,h   Günthard, Huldrych F ^c   Rickenbach, Martin ^b   Nicca, Dunja ^d   Hirschel, Bernard ^e   Bernasconi, Enos ^f   Wandeler, Gilles ^g   Battegay, Manuel ^h   Marzolini, Catia ^h  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f REGIONAL HOSPITAL OF LUGANO   (Switzerland)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

ⁱ UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABC TRANSPORTER; ABC TRANSPORTER C2; CYTOCHROME P450 2B6; CYTOCHROME P450 3A; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; ORGANIC ANION TRANSPORTER 2; STAVUDINE; TENOFOVIR; UNCLASSIFIED DRUG; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ABCC2 GENE; ADULT; ARTICLE; CAUCASIAN; CONFIDENCE INTERVAL; CONTROLLED STUDY; CYP2B6 GENE; CYP3A GENE; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PROBABILITY; RISK ASSESSMENT; SELF REPORT; SINGLE NUCLEOTIDE POLYMORPHISM; SLCO1B1 GENE; VIRUS INHIBITION; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MIDDLE AGED; STATISTICAL MODEL; STATISTICS; TIME; VIROLOGY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; ANTI-HIV AGENTS; HIV INFECTIONS; HIV-1; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PATIENT COMPLIANCE; SELF REPORT; TIME FACTORS;

EID: 84855315430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029186     Document Type: Article

References (29)

1. Paterson DL, Swindells S, Mohr J, Brester M, Vergis EN, et al. (2000) Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med 133: 21-30.
2. Bangsberg DR, (2006) Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clin Infect Dis 43: 939-941.
3. Maggiolo F, Ravasio L, Ripamonti D, Gregis G, Quizan G, et al. (2005) Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis 40: 158-163.
4. Lima VD, Harrigan R, Murray M, Moore DM, Wood E, et al. (2008) Differential impact of adherence on long-term treatment response among naive HIV-infected individuals. AIDS 22: 2371-2380.
5. Marzolini C, Buclin T, Decosterd LA, Biollaz J, Telenti A, (2001) Nelfinavir plasma levels under twice-daily and three-times-daily regimens: high interpatient and low intrapatient variability. Ther Drug Monit 23: 394-398.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, et al. (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15: 71-75.
7. Telenti A, Zanger UM, (2008) Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol 48: 227-256.
8. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, et al. (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS 18: 2391-2400.
9. Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, et al. (2009) Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 85: 485-494.
10. Schoeni-Affolter F, Ledergerber B, Rickenbach M, Rudin C, Günthard HF, et al. (2010) Cohort profile: the Swiss HIV Cohort study. Int J Epidemiol 39: 1179-1189.
11. Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, et al. (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIV-infected individuals. Clin Pharmacol Ther 81: 557-566.
12. Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, et al. (2010) ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir. Pharmacogenet Genomics 20: 217-230.
13. Colombo S, Beguin A, Telenti A, Biollaz J, Buclin T, et al. (2005) Intracellular measurements of anti-HIV drugs indinavir, amprenavir, saquinavir, ritonavir, nelfinavir, lopinavir, atazanavir, efavirenz and nevirapine in peripheral blood mononuclear cells by liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 819: 259-276.
14. Fayet A, Beguin A, de Tejada BM, Colombo S, Cavassini M, et al. (2008) Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 30: 511-522.
15. Csajka C, Marzolini C, Fattinger K, Decosterd L, Fellay J, et al. (2003) Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73: 20-30.
16. Glass TR, De Geest S, Hirschel B, Battegay M, Furrer H, et al. (2008) Self-reported non-adherence to antiretroviral therapy repeatedly assessed by two questions predicts treatment failure in virologically suppressed patients. Antivir Ther 13: 77-85.
17. Ribaudo HJ, Haas DW, Tierney C, Kim RB, Wilkinson GR, et al. (2006) Pharmacogenetics of plasma efavirenz exposure after treatment discontinuation: an Adult AIDS Clinical Trials Group Study. Clin Infect Dis 42: 401-407.
18. Martin M, Del Cacho E, Codina C, Tuset M, de Lazzari E, et al. (2008) Relationship between adherence level, type of the antiretroviral regimen, and plasma HIV type 1 RNA viral load: a prospective cohort study. AIDS Res Hum Retroviruses 24: 1263-1268.
19. Nachega JB, Hislop M, Dowdy DW, Chaisson R, Regensberg L, et al. (2007) Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes. Ann Intern Med 146: 564-573.
20. Shuter J, Sarlo JA, Kanmaz TJ, Rode RA, Zingman BS, (2007) HIV-infected patients receiving lopinavir/ritonavir-based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%. J Acquir Immune Defic Syndr 45: 4-8.
21. Pearson CR, Simoni JM, Hoff P, Kurth AE, Martin DP, (2007) Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues. AIDS Behav 11: 161-173.
22. Wagner G, Miller LG, (2004) Is the influence of social desirability on patients' self-reported adherence overrated? J Acquir Immune Defic Syndr 35: 203-204.
23. King MS, Brun SC, Kempf DJ, (2005) Relationship between adherence and the development of resistance in antiretroviral-naive, HIV-1-infected patients receiving lopinavir/ritonavir or nelfinavir. Journal of Infectious Diseases 191: 2046-2052.
24. von Wyl V, Yerly S, Boni J, Burgisser P, Klimkait T, et al. (2007) Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 167: 1782-1790.
25. Boffito M, Else L, Back D, Taylor J, Khoo S, et al. (2008) Pharmacokinetics of atazanavir/ritonavir once daily and lopinavir/ritonavir twice and once daily over 72 h following drug cessation. Antivir Ther 13: 901-907.
26. Lima VD, Bangsberg DR, Harrigan PR, Deeks SG, Yip B, et al. (2010) Risk of viral failure declines with duration of suppression on highly active antiretroviral therapy irrespective of adherence level. J Acquir Immune Defic Syndr 55: 460-465.
27. Rosenblum M, Deeks SG, van der Laan M, Bangsberg DR, (2009) The risk of virologic failure decreases with duration of HIV suppression at greater than 50% adherence to antiretroviral therapy. PLoS One 4: e7196.
28. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, et al. (2003) Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A 100: 4819-4824.
29. Corbeau P, Reynes J, (2011) Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood 117: 5582-5590.